CME 4 Session – EANM’12


Development of 18F-Labelled Radioligands for Clinical Applications in Neurology and Psychiatry

Educational objectives:

  1. To have an overview of the available 18F-PET probes
  2. To understand the importance of radioligand development
  3. To review of the advantages of 18F-PET radioligands for diagnostic clinical use in neurodegenerative disorders

The advancement in PET methodology and the wider availability of PET/CT systems in nuclear medicine departments have made PET a largely available technique for clinical and diagnostic imaging. The advancement in radioligand development in the area of amyloid imaging has contributed with new 18F-labelled probes to be used for the diagnostic assessment of patients with dementia. In this context, the development of new PET radioligands for application in clinical setting could be of major advantage for improving disease diagnosis and patient care. In this CME, the development of new 18F-radioligands for imaging the dopamine transporter (DAT), the vesicular monoamine transporter type 2 (VMAT2), and the cannabinoid receptor (CB) will be presented, in addition with an update on the status of the available radioligands for amyloid imaging. The aspects related to the radioligand development and the potential advantages for diagnostic clinical use in neurodegenerative disorders will be discussed.

Key Words:
Dopamine, Vesicular Monoamine, Amyloid Plaques, Cannabinoid, PET, Radioligands, Quantification, Imaging Biomarkers


User action required
If you have the permission to view this publication, please log in.